NATCOPHARM.NS Profit & Loss
NATCO Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 6 years on file
(FY2020-21 to FY2025-26)
· fetched 2026-08-23 23:38
| Line item | FY2020-21 | FY2021-22 | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹2,052.10 Cr. | ₹1,944.80 Cr. | ₹2,707.10 Cr. | ₹3,998.80 Cr. | ₹4,429.50 Cr. | ₹4,078.30 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | ₹2,052.10 Cr. | ₹1,944.80 Cr. | ₹2,707.10 Cr. | ₹3,998.80 Cr. | ₹4,429.50 Cr. | ₹4,078.30 Cr. | SegmentRevenueFromOperations |
| Other Income | ₹103.60 Cr. | ₹99.00 Cr. | ₹104.60 Cr. | ₹128.10 Cr. | ₹354.50 Cr. | ₹297.60 Cr. | OtherIncome |
| Total Income | ₹2,155.70 Cr. | ₹2,043.80 Cr. | ₹2,811.70 Cr. | ₹4,126.90 Cr. | ₹4,784.00 Cr. | ₹4,375.90 Cr. | Income |
| Cost of Materials Consumed | ₹372.90 Cr. | ₹519.20 Cr. | ₹475.30 Cr. | ₹522.50 Cr. | ₹536.20 Cr. | ₹593.50 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹186.60 Cr. | ₹58.50 Cr. | ₹175.70 Cr. | ₹151.40 Cr. | ₹166.10 Cr. | ₹203.20 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-48.10 Cr. | ₹-16.80 Cr. | ₹-23.70 Cr. | ₹42.70 Cr. | ₹-12.50 Cr. | ₹-106.20 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹414.90 Cr. | ₹444.80 Cr. | ₹486.70 Cr. | ₹525.00 Cr. | ₹594.50 Cr. | ₹687.20 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹13.30 Cr. | ₹17.70 Cr. | ₹14.50 Cr. | ₹19.20 Cr. | ₹23.90 Cr. | ₹36.70 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹116.90 Cr. | ₹142.60 Cr. | ₹163.80 Cr. | ₹186.80 Cr. | ₹235.20 Cr. | ₹206.60 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹519.60 Cr. | ₹675.60 Cr. | ₹657.50 Cr. | ₹1,005.80 Cr. | ₹949.20 Cr. | ₹1,264.10 Cr. | OtherExpenses |
| Total Expenses | ₹1,576.10 Cr. | ₹1,841.60 Cr. | ₹1,949.80 Cr. | ₹2,453.40 Cr. | ₹2,492.60 Cr. | ₹2,885.10 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹579.60 Cr. | ₹202.20 Cr. | ₹861.90 Cr. | ₹1,673.50 Cr. | ₹2,291.40 Cr. | ₹1,490.80 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹579.60 Cr. | ₹202.20 Cr. | ₹861.90 Cr. | ₹1,673.50 Cr. | ₹2,291.40 Cr. | ₹1,490.80 Cr. | ProfitBeforeTax |
| Tax Expense | ₹137.20 Cr. | ₹32.20 Cr. | ₹146.60 Cr. | ₹285.20 Cr. | ₹408.00 Cr. | ₹118.90 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹442.40 Cr. | ₹170.00 Cr. | ₹715.30 Cr. | ₹1,388.30 Cr. | ₹1,883.40 Cr. | ₹1,418.50 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹440.90 Cr. | ₹170.00 Cr. | ₹715.30 Cr. | ₹1,388.30 Cr. | ₹1,885.40 Cr. | ₹1,418.50 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹24.20 | ₹9.32 | ₹39.18 | ₹77.34 | ₹105.26 | ₹79.20 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹24.16 | ₹9.32 | ₹39.18 | ₹77.34 | ₹105.26 | ₹79.20 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from NATCOPHARM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).